The underlying mechanisms that lysosomal acid lipase (LAL) deficiency causes infiltration of myeloid-derived suppressor cells (MDSCs) in multiple organs and subsequent inflammation remain incompletely understood. Endothelial cells (ECs), lining the inner layer of blood vessels, constitute barriers regulating leukocytes transmigration to the site of inflammation. Therefore, we hypothesized that ECs are dysfunctional in LAL-deficient (lal −/− ) mice. We found that Ly6G + cells transmigrated more efficiently across lal −/− ECs than wild-type (lal +/+ ) ECs, which was associated with increased level of platelet endothelial cell adhesion molecule-1 (PECAM-1) and monocyte chemoattractant protein-1 (MCP-1) in lal −/− ECs. In addition, lal −/− ECs showed enhanced migration and proliferation, decreased apoptosis, but impaired tube formation and angiogenesis. lal −/− ECs also suppressed T cell proliferation in vitro. Interestingly, lal −/− Ly6G + cells promoted in vivo angiogenesis (including a tumor model), EC tube formation and proliferation. Finally, the mammalian target of rapamycin (mTOR) pathway was activated in lal −/− ECs, and inhibition of mTOR reversed EC dysfunctions, including decreasing Ly6G + cell transmigration, delaying migration, and relieving suppression of T cell proliferation, which was mediated by decreasing production of reactive oxygen species (ROS). Our results indicate that LAL regulates EC functions through interaction with MDSCs and modulation of the mTOR pathway, which may provide a mechanistic basis for targeting MDSCs or mTOR to rejuvenate EC functions in LAL-deficiency related diseases.
Introduction
Lysosomal acid lipase (LAL) hydrolyzes cholesteryl esters and triglycerides in the lysosome of cells to generate free fatty acids and cholesterol. LAL deficiency has been reported to result in pulmonary inflammation, which is associated with neutrophil infiltration, increases of foamy macrophages and alternation of proinflammatory cytokines/chemokines (1, 2) .
Transwell assay
Transwell assay was used to determine MDSC transendothelial migration. ECs were collected by Accutase (Sigma-Aldrich) digestion. Around 5×10 4 cells in 250 μL media were added to the upper chamber of 24-well 6.5-μm-pore Transwell plates (Corning, Corning, NY, USA), while 500 μL media was placed in the lower chamber. Cells were incubated at 37°C, 5% CO 2 for 48 h to form an EC monolayer. Then the supernatant was removed, and CellTracker TM Green 5-Chloromethylfluorescein Diacetate (CMFDA) (Invitrogen, Grand Island, NY, USA)-labeled MDSCs (1×10 4 cells in 250 μL media) were added to the upper well. The media in the lower chamber was replaced with the same media as the upper chamber. After 6 h, transendothelial migration of MDSCs was determined by counting their numbers in the lower chamber under 5 random microscopic fields. For the neutralization study, ECs were pretreated with 10 μg/mL neutralizing antibody against PECAM-1, MCP-1, IL-6, TNF-α or control IgG for 1h.
Tube formation assay
The in vitro angiogenic activity of ECs was determined by matrigel tube formation assay as previously described (22) . Briefly, ECs were seeded at a density of 5×10 4 cells/well in 48-well plates precoated with 150 μL/well growth factor-reduced matrigel (BD Biosciences, San Jose, CA, USA). After 6 h of incubation, tube formation was observed with an inverted microscope with image capture system (Nikon, Melville, NY, USA). Tube formation was defined as a tube-like structure exhibiting a length four times its width (23) . To detect the effect of MDSCs on EC tube formation, MDSCs and ECs were co-cultured overnight. Images of tube morphology were taken in 5 random microscopic fields per sample at × 40 magnification, and the cumulative tube lengths were measured by Image-Pro Plus software (Media Cybernetics, Rockville, MD, USA).
In vitro wound healing assay
In vitro wound healing assay was performed to analyze EC migration as previously described (24) . Briefly, ECs were seeded at a density of 1.5×10 5 cells/well into a 24-well plate and incubated overnight to form a confluent monolayer. Scratch was created by scraping the cell monolayer in a straight line with a p200 pipet tip. After washing 3 times with PBS, the medium was changed with DMEM containing 10% FBS and 5 μg/mL mitomycin C (Sigma-Aldrich), and ECs were kept on culture at 37°C, 5% CO 2 . Images were taken at 0 and 15 h after creating the scratch. Migration was estimated by measuring the distances from one side of scratch to the other side using Image Pro-Plus software (Media Cybernetics).
Small interfering RNA transfection
Before transfection, ECs were seeded into 6-well plates at a density of 2.5×10 5 cells/well and incubated overnight. For small interfering RNA (siRNA)-mediated gene knockdown, 50 nmol/L of mTOR siRNA SMARTpool, platelet endothelial cell adhesion molecule-1 (PECAM-1, PECAM, CD31) siRNA SMARTpool, vascular endothelial growth factor receptor 2 (VEGFR2) siRNA SMARTpool or control siRNA (Dharmacon, Chicago, IL, USA) were transfected into cells with DharmaFECT Transfection Reagent IV (Dharmacon) according to the manufacturer's protocol. After 72 hours of transfection, cells were harvested for further analysis.
Western blot analysis
Western blot analysis was performed as previously described (22) . Briefly, ECs were lysed in Cell Lytic MT lysis buffer (Sigma-Aldrich) with Protease Inhibitor Cocktail (Invitrogen) for 15 minutes on a shaker. After centrifugation for 10 minutes at 12,000×g (4°C), the supernatants were saved and protein concentrations of the samples were determined using the Pierce BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA). Equal amounts of protein (30 μg) were loaded onto SDS-polyacrylamide gels and blotted onto PVDF membranes (BioRad, Hercules, CA, USA). Western blots analysis used antibodies against mTOR downstream S6, and p-S6 (rabbit monoclonal antibodies, 1:1,000, Cell Signaling, Beverly, MA, USA), PECAM-1 (rabbit polyclonal anti-PECAM-1, 1:1,000, Abcam, Cambridge, MA, USA) and intercellular adhesion molecule-2 (ICAM-2) (rabbit polyclonal anti-ICAM-2, 1:200, Santa Cruz, Dallas, Texas, USA). Antibody against β-actin (rabbit monoclonal anti-β-actin, 1:2,000, Cell Signaling) was used as a loading control. For detection, the membrane was incubated with anti-rabbit IgG secondary antibodies conjugated with horseradish peroxidase (1:2,000, Cell Signaling). Bands were visualized using SuperSignal West Pico Chemiluminescent substrate (ThermoScientific Pierce, Rockford, IL, USA).
Annexin V staining
Dual staining with FITC-annexin V and propidium iodide (PI) was performed to detect cells undergoing apoptosis using an annexin V-FITC kit (BD Biosciences) as we described previously (10) . Single lung cells were first stained with endothelial marker CD31. After washing with PBS, labeled cells were resuspended in annexin V-binding buffer containing FITC-conjugated annexin V. PI was then added into cells and incubated on ice for 10 min. Nonspecific binding was blocked by pre-incubating cells with rat IgG (10 mg/mL) and antiFcII/III. Cells were analyzed on a LSRII machine (Becton Dickinson, Franklin Lakes, New Jersey, USA) within 1 h. Viable cells were defined by FITC -and PI -population. Early apoptotic cells were defined by FITC + and PI -population.
In vitro co-culture of ECs and MDSCs
ECs were resuspended and adjusted to density at 5×10 4 cells/mL. MDSCs after MACS sorting were used immediately and the cell density was adjusted to 5×10 6 cells/mL. One hundred microliters of MDSCs and 100 μL of ECs were mixed, and seeded into a well of 96-well plates. Seventy-two hours later, unattached MDSCs were removed by washing with PBS, and the number of attached ECs was counted. Morphologically, MDSCs are much smaller than ECs.
BrdU incorporation
Immunofluorescent staining of incorporated bromodeoxyuridine (BrdU) was also performed on ECs after coculture with MDSCs for 3 days and washing off the MDSCs by PBS, followed by flow cytometric analysis. BrdU incorporation was performed using the BrdU Flow Kit (BD Biosciences) as we previously described (10) . Briefly, BrdU was added to cells at a final concentration of 10 μmol/L. One hour later, cells were collected and fixed. After permeabilisation, cells were incubated with DNase I at 37°C for 1 h, followed by labeling with anti-BrdU antibody for 20 min at room temperature. Cells were then analyzed by flow cytometry.
In vivo matrigel plug assay with ECs or MDSCs
This assay was performed according to established methods with minor modifications (25) . ECs or MDSCs were collected separately. After washed with PBS, 1×10 6 ECs or 2×10 6 MDSCs were centrifuged and resuspended in 40 μL PBS and mixed with 500 μL Matrigel Basement Membrane Matrix (BD Biosciences) containing 15 units of heparin (SigmaAldrich). The cell-matrigel-mixture was then injected subcutaneously into the abdomen of 3-month old lal +/+ mice. For the B16 melanoma tumor model, 1×10 6 MDSCs and 1×10 5 B16 melanoma cells were mixed in 500 μL matrigel, and then injected subcutaneously into lal +/+ mice. After 10 days, the mice were sacrificed and plugs were harvested from underneath the skin. The plugs were fixed, embedded, sectioned, stained with H&E, and then examined using microscopy. To visualize capillaries, samples were immunohistochemically stained with anti-CD31 antibody. For hemoglobin analysis, the matrigel plugs were removed after 10 days and homogenized in 130 μL de-ionized water. After centrifugation, the supernatant was harvested, and then used in the Drabkin assay (Sigma-Aldrich) to measure hemoglobin concentration. Stock solutions of hemoglobin are used to generate a standard curve. Results are expressed relative to total protein in the supernatant.
T cell proliferation assay and lymphokine measurement by ELISA CD4 + T cells were prepared and CFSE labeled as we previously described (26) . Labeled CD4 + T cells were co-cultured with ECs in 96-well plates pre-coated with anti-CD3 monoclonal antibody (mAb) (2 μg/mL) and anti-CD28 mAb (5 μg/mL) at 37°C, 5% CO 2 for 4 d. The ratio of ECs/CD4 + T cells was 1:10. Proliferation of CD4 + T cells was evaluated as CFSE dilution by FACS. The expression level of IL-4, IL-10, IFN-γ, and IL-17 in the supernatants of the culture medium was measured using ELISA kits (BD Biosciences).
Real-time RT-PCR
Total RNAs from ECs or Ly6G + cells were purified using the Qiagen total RNA purification kit (Qiagen, Valencia, CA, USA). Quantitative (q)RT-PCR was performed as described previously (20) . Analysis was performed by the 2 −ΔΔCT method. Primers of mMCP-1, mCCR2, mIL-6, mTNF-α, VEGF and GAPDH for real-time PCR were described previously (20) .
Flow Cytometry Analysis
After 7 days of culture, ECs were harvested and washed with PBS. To detect VEGFR-2 expression level, cells were incubated with APC-conjugated anti-mouse VEGFR-2 antibody (eBioscience, San Diego, CA, USA). For flow cytometry analysis, ≥10,000 cells were acquired and scored using a LSRII machine (Becton Dickinson). Data were processed using the CellQuest software program (Becton Dickinson).
ROS Measurement
The reactive oxygen species (ROS) level in ECs was measured by flow cytometry as we previously described (13) . Briefly, ECs were harvested, washed, and stained with 2 μmol/L 2′, 7′-dichlorofluorescein diacetate (Invitrogen) at 37°C for 30 min. After PBS wash, the ROS level was analyzed using a LSRII machine (Becton Dickinson). In a ROS inhibition assay, the antioxidant N-Acetyl-L-cysteine (NAC) (Sigma-Aldrich) was added to ECs twice per day for 3 days, followed by further analysis.
Statistics
Data were expressed as mean ± SD. Differences between two treatment groups were compared by Student's t-test. When more than two groups were compared, one-way ANOVA with post-hoc Newman-Keul's multiple comparison test was used. Results were considered statistically significant when P < 0.05. All analyses were performed with GraphPad Prism 5.0 (GraphPad, San Diego, CA, USA).
Results

LAL deficiency in ECs led to increased transendothelial migration of MDSCs
Transendothelial migration of leukocytes is a critical step in the inflammatory response, during which ECs participate in regulating leukocyte transmigration from the vasculature to the site of inflammation (27) . Because we have previously reported that LAL deficiency results in severe infiltration of MDSCs in multiple organs (1, 10, 12, 28, 29) , the role of ECs in MDSC infiltration was investigated. Transwell assay was performed to determine MDSC transmigration across the endothelial monolayer formed by ECs isolated from lungs of lal +/+ or lal −/− mice. ECs were seeded into Transwell upper chambers and grown to confluence. Freshly isolated bone marrow-derived Ly6G + cells (MDSCs) from lal +/+ or lal −/− mice were labeled with CMFDA and then loaded on the EC monolayers. In lal −/− mice, since almost all Ly6G + cells are positive for CD11b, which showed T cell suppression, Ly6G antibody was used for purification of Ly6G + CD11b + cells (30) . Six hours later, the number of Ly6G + cells that had migrated to the lower chamber was counted. As shown in Figure 1A , when lal +/+ Ly6G + cells were added to the EC monolayer, lal −/− ECs showed increased permeability, with more Ly6G + cells in the lower chamber, than that of lal +/+ ECs. In addition, we repeated the experiments using lal −/− Ly6G + cells to migrate across lal +/+ or lal −/− EC monolayers, and there were more lal −/− Ly6G + cells migrating to the lower chamber through lal −/− ECs than lal +/+ ECs. These data suggest that 1) the increased permeability of lal −/− ECs is a potential mechanism of increased Ly6G + cell infiltration in the lal −/− mice and 2) lal −/− Ly6G + cells possess a stronger ability to transmigrate the pulmonary EC monolayer. As a matter of fact, lal −/− Ly6G + cell and lal −/− EC combination showed three times more permeability than that of lal +/+ Ly6G + cell and lal +/+ EC combination. In addition to Ly6G + cells, lal −/− CD4 + T cells also showed increased ability of transendothelial migration, with similar results as Ly6G + cells ( Figure 1B ).
A number of adhesion molecules have been implicated in the process of leukocyte transendothelial migration (27) . It is plausible that increased expression of adhesion molecules in lal −/− ECs facilitates Ly6G + cell transmigration across the endothelial monolayer. Among several tested proteins, Western blot analysis showed that expression of PECAM-1 and ICAM-2 was both elevated in lal −/− ECs ( Figure 1C ). To assess functional roles of PECAM-1 in ECs for Ly6G + cell transendothelial migration, siRNA transfection was performed to knockdown PECAM-1 expression in ECs. Results of Transwell assay showed that there were less migrated Ly6G + cells in the groups of lal +/+ and lal −/− ECs with PECAM-1 siRNA transfection than their counterparts with control siRNA transfection ( Figure 1D ). Furthermore, ECs were treated with anti-PECAM-1 neutralizing antibodies. As Figure 1E demonstrated, the transmigration of Ly6G + cells across the EC monolayer was reduced in the groups of ECs with anti-PECAM-1 antibody treatment compared to those treated with control IgG. Taken together, increased expression of PECAM-1 in lal −/− ECs contributed to enhanced Ly6G + cell transmigration.
Moreover, chemokines secreted by ECs are crucial in recruiting monocytes into the vessel wall, among which MCP-1 plays a major role (31, 32) . In lal −/− ECs, the mRNA level of MCP-1 was up-regulated by a Real-time PCR analysis ( Figure 1F ). Accordingly, expression of MCP-1 receptor -CCR2 was increased in lal −/− Ly6G + cells ( Figure 1G ). To examine whether MCP-1 secreted by lal −/− ECs facilitated Ly6G + cell migration, transwell study was performed with ECs pre-treated with anti-MCP-1 neutralizing antibodies. As shown in Figure 1H , fewer Ly6G + cells transmigrated through ECs treated with anti-MCP-1 antibody than those treated with control IgG. In addition, the mRNA levels of IL-6 and TNFα were increased in lal −/− ECs ( Figure 1F ), both of which have been reported to be involved in EC permeability (33, 34) . After ECs were pre-treated with anti-IL-6 or anti-TNFα antibodies to neutralize cytokines, Ly6G + cell transmigration was not significantly inhibited. However, combination of all three neutralizing antibodies (anti-MCP-1, anti-IL-6 and anti-TNFα antibodies) showed a stronger blocking on Ly6G + cell transmigration ( Figure 1H ). Therefore, chemokines and cytokines, especially MCP-1, secreted by lal −/− ECs are responsible for mediating Ly6G + cell transendothelial migration.
LAL deficiency influenced EC angiogenic functions
Angiogenesis is a feature of chronic inflammation, a process ECs actively participate in (3). Three studies were designed to assess angiogenic functions. Firstly, an important aspect of angiogenesis involves the formation of capillary-like tubes by ECs (35) . To determine whether LAL deficiency influences tube formation, in vitro matrigel tube formation assay was performed. As shown in Figure 2A , 6 h after seeding on matrigel, lal −/− ECs formed significantly less completed and poorly connected tube networks than those of lal +/+ ECs. Statistical results showed that there was more than 50% decrease in the total tube lengths in lal −/− ECs compared with those of lal +/+ ECs, demonstrating that LAL deficiency impaired EC tube formation in vitro. Interestingly, tube networks formed by lal −/− ECs showed a delayed disappearance compared with those formed by lal +/+ ECs at 12h and 24h.
Secondly, we investigated the effect of LAL deficiency on EC-mediated in vivo angiogenesis by in vivo matrigel plug assay. Fourteen days after subcutaneous injection of EC-matrigel-mixture, the mice were sacrificed and plugs were harvested, sectioned, and stained with H&E. The presence of capillaries in the matrigel was further detected by immunohistochemical (IHC) staining with anti-CD31 antibody. Results showed that administration of lal +/+ ECs induced formation of vessel-like structures and the presence of erythrocytes were evidenced in the lumen ( Figure 2B , see arrows), while administration of lal −/− ECs led to formation of disorganized cell clusters, demonstrating that LAL deficiency in ECs impaired their in vivo angiogenic function. As a control, plugs without ECs showed no vessel formation or CD31 + cells (data not shown), confirming that the above observations were from extrinsic ECs. In addition, the hemoglobin content (a surrogate marker of perfusion) was significantly lowered in the plugs mixed with lal −/− ECs ( Figure  2C ).
Thirdly, endothelial cell migration is an essential component of angiogenesis (36) . To test whether LAL deficiency in ECs affects their migration ability, we performed the in vitro wound healing assay. ECs were treated with mitomycin C to eliminate the potential effects of EC proliferation. As shown in Figure 2D , 15 h after creating the scratch, lal −/− ECs demonstrated increased migration compared with that of lal +/+ ECs, evidenced by a significant reduction in the wound area lacking cells. This indicates that LAL deficiency facilitates EC migration.
LAL deficiency facilitated EC proliferation
Cell proliferation is essential for ECs to adequately perform their functions. Therefore, the effect of LAL deficiency on EC proliferation was determined. CD31 + ECs from the lungs of lal +/+ or lal −/− mice were isolated and counted. There were significantly more CD31 + cells in the lungs of lal −/− mice than those in the lungs of lal +/+ mice ( Figure 3A ). When cultured in vitro, lal −/− ECs demonstrated increased proliferation compared with that of lal +/+ ECs ( Figure 3B ). The BrdU incorporation study further supported increased proliferation of lal −/− ECs ( Figure 3C ). Since apoptosis may contribute to the numbers of ECs, we further examined the apoptotic activity in isolated lung ECs by Annexin V staining. The percentage of Annexin V positive cells in lung CD31 + cells was compared between lal +/+ and lal −/− mice. As shown in Figure 3D , apoptosis in lal −/− lung CD31 + cells was decreased compared with those of lal +/+ mice. The abnormality of lal −/− EC proliferation is a complicated process, which can be influenced by environmental factors. In addition to the above intrinsic defects in ECs, we also investigated the effect of blood plasma on EC proliferation. Plasma was prepared from both lal +/+ and lal −/− blood, and added into culture medium (20% plasma) of ECs. Seventy-two hours later, lal −/− plasma exerted a greater stimulatory effect on both lal +/+ and lal −/− EC proliferation, compared with that of lal +/+ plasma ( Figure 3E ). Since lal −/− ECs showed more sensitivity to plasma treatment, the potential mechanism contributing to EC growth was investigated. VEGF has been found to have various functions on ECs, the most prominent of which is the stimulation of proliferation and angiogenesis (37, 38) . The VEGF level was indeed increased in lal −/− plasma (data not shown). Therefore, the level of its receptor VEGFR2 was examined in lal +/+ vs. lal −/− ECs. Flow cytometry analysis showed that the expression level of VEGFR2 was increased in lal −/− ECs ( Figure 3F ). After VEGFR2 knockdown in ECs, the stimulatory effect of lal −/− plasma on EC proliferation was impaired ( Figure 3G ). These results indicate that both intrinsic defects and environmental factors contribute to abnormal proliferation of lal −/− ECs.
LAL deficiency in ECs suppressed T cell proliferation
Increased T cell permeability across the ECs monolayer ( Figure 1B ) triggered us to further investigate ECs' effects on T cell proliferation and functions. ECs have been found to function as antigen presentation cells, leading to activation of T cells (39, 40) . We have previously reported that LAL deficiency impaired T cell proliferation and function in lal −/− mice (26) . Although the intrinsic defect and lal −/− MDSC suppression contribute to T cell paucity (26) , whether lal −/− ECs participate in T cell suppression has not been investigated. CFSE-labeled lal +/+ CD4 + T cells were cultured in vitro and stimulated with anti-CD3 mAb plus anti-CD28 mAb in the presence or absence of lal +/+ or lal −/− ECs for 4 d. Proliferation of CD4 + T cells was evaluated by CFSC dilution (cell division). As demonstrated in Figure  4A , lal −/− ECs showed inhibition on proliferation of lal +/+ CD4 + T cells after anti-CD3 mAb plus anti-CD28 mAb stimulation, whereas lal +/+ ECs had no effects on CD4 + T cell proliferation. In the PBS control group, no proliferation was observed. Furthermore, the secretion of CD4 + T lymphokines, e.g. IFN-γ (Th1), IL-4 and IL-10 (Th2) was also inhibited by lal −/− ECs, while the secretion of Th17 lymphokine IL-17 remained unchanged ( Figure  4B ). Therefore, lal −/− ECs suppressed both T cell proliferation and lymphokine secretion.
Interaction with MDSCs leads to EC dysfunctions
Our previous publications have demonstrated that the MDSC population in lal −/− mice was significantly increased in multiple organs (10) (11) (12) . The synergism between Ly6G + cells and ECs in the lal −/− mice has been implicated in Figure 1A , in which not only lal −/− ECs had enhanced permeability for Ly6G + cells, but also lal −/− Ly6G + cells had greater transmigration capability than that of lal +/+ Ly6G + cells. It is intriguing to determine if lal −/− Ly6G + cells influence EC proliferation and functions. To test whether Ly6G + cells contribute to angiogenesis, the EC tube formation assay was performed in the presence of Ly6G + cells. In this study, both lal +/+ and lal −/− Ly6G + cells facilitated lal −/− EC tube formation ( Figure 5A ). Despite impaired tube formation in the absence of Ly6G + cells, lal −/− ECs co-cultured with lal −/− Ly6G + cells formed more complete tube networks than those with lal +/+ Ly6G + cells, suggesting that lal −/− Ly6G + cells exert proangiogenic effects on ECs. However, when ECs were co-cultured with macrophages (F4/80 + and CD11b + ) that were isolated from lal +/+ or lal −/− mice, lal +/+ macrophages stimulated tube formation on ECs, while lal −/− macrophages did not ( Figure 5B ). This difference indicates differential abilities between lal +/+ and lal −/− macrophages to stimulate EC tube formation. In a similar study, both lal +/+ and lal −/− CD4 + T cells showed no effect on EC tube formation ( Figure  5B ).
In the in vivo matrigel plug assay, matrigel mixed with either lal +/+ or lal −/− Ly6G + cells were injected into lal +/+ mice subcutaneously. Fourteen days after implantation, matrigel plugs containing lal −/− Ly6G + cells showed more CD31 + cells than those containing lal +/+ Ly6G + cells. H&E staining results revealed newly formed microvessels in the plugs containing lal −/− Ly6G + cells ( Figure 5C, see arrows) . The effect of Ly6G + cells on angiogenesis in vivo was further examined in a B16 melanoma tumor model, a system that was recently established by us (14) . lal +/+ or lal −/− Ly6G + cells were isolated and mixed with B16 melanoma cells in matrigel. The mixture was subcutaneously injected into wild type recipient mice for tumor growth study. IHC staining showed that more CD31 + cells appeared in matrigel plugs containing lal −/− Ly6G + cells than those containing lal +/+ Ly6G + cells ( Figure 5D ). The underlying mechanism of this proangiogenic activity was further investigated. The mRNA level of VEGF, a crucial factor in regulating EC angiogenesis, was up-regulated in lal −/− Ly6G + cells ( Figure 5E ). On the other hand, inhibition of VEGF receptor 2 (VEGFR2) expression by siRNA knockdown in ECs decreased the tube-forming activity by lal −/− Ly6G + cells (Figure 5F ), suggesting that VEGF secreted by lal −/− Ly6G + cells is responsible for the pro-angiogenic activity.
The effect of Ly6G + cells on EC proliferation was also determined. ECs were co-cultured with lal +/+ or lal −/− Ly6G + cells for 72 h, and the numbers of ECs were counted. As shown in Figure 5G , ECs co-cultured with lal −/− Ly6G + cells showed more proliferative cells than those with lal +/+ Ly6G + cells. lal −/− ECs co-cultured with lal −/− Ly6G + cells showed the highest proliferation, which was consistent with Figure 3A , in which proliferation of CD31 + cells was increased in lal −/− mice. This observation was further supported by BrdU incorporation assay, showing significant increase of BrdU incorporation when ECs were cocultured with lal −/− Ly6G + cells ( Figure 5H ).
Over-activation of the mTOR pathway is responsible for EC dysfunctions
In lal −/− mice, over-activation of the mTOR pathway has been identified in bone marrowderived MDSCs (13, 14, 17) . Interestingly, Western blot analysis also detected increased level of phosphorylated-S6, a downstream target protein of mTOR (41) , in lal −/− ECs ( Figure 6A ). Knocking down mTOR expression in lal −/− ECs by siRNA transfection showed significant decrease of phosphorylated-S6 compared with lal −/− ECs transfected with control siRNA ( Figure 6B ). These results implied pathogenic roles of mTOR over-activation in lal −/− ECs. To see if the mTOR pathway plays roles in lal −/− EC dysfunctions, the effect of mTOR inhibition in lal −/− ECs on Ly6G + cell transendothelial migration was analyzed by Transwell assay. After ECs were transfected with mTOR or control siRNA for 48 h, Ly6G + cells were added to the lal +/+ or lal −/− EC monolayer. Six hours later, the number of Ly6G + cells in the lower chamber was significantly less across both lal +/+ and lal −/− ECs transfected with mTOR siRNA than those across ECs with control siRNA transfection ( Figure 6C ), suggesting that mTOR inhibition in ECs reduces Ly6G + cell transendothelial migration. Furthermore, the in vitro wound healing assay showed delayed migration towards the scratch in lal −/− ECs with mTOR siRNA transfection at 12 h and 18 h after creating the scratch, with a significant increase of distance in the wounding area ( Figure 6D ), indicating mTOR inhibition impairs the increased migration of lal −/− ECs. Finally, mTOR inhibition in lal −/− ECs reversed their suppressive activity on T cells. As demonstrated in Figure 6E , lal −/− ECs with control siRNA transfection showed inhibition on T cell proliferation, whereas lal −/− ECs with mTOR siRNA transfection displayed reduced inhibition on T cell proliferation. lal −/− ECs with mTOR siRNA transfection also reversed decreased secretion of IL-4, IL-10 and IFN-γ by T cells ( Figure 6F ).
Over-production of ROS mediates the over-activation of mTOR pathway in EC dysfunction
ROS over-production has been observed, and rapamycin treatment decreased the ROS level in lal −/− Ly6G + MDSCs (13, 17) . Similarly, the ROS level was also increased in lal −/− ECs, and rapamycin treatment suppressed ROS production in lal −/− ECs ( Figure 7A ). To see if the ROS over-production mediates the mTOR signaling in EC dysfunctions, ECs were treated with antioxidant NAC to neutralize ROS. In the transendothelial migration study, NAC pre-treatment of ECs significantly reduced both lal +/+ and lal −/− Ly6G + cell migration across the ECs monolayer ( Figure 7B ). The same EC treatment also improved tube formation of lal −/− ECs ( Figure 7C ), and delayed lal −/− EC migration towards the scratch with a significant increase of distance in the wounding area in the in vitro wound healing assay ( Figure 7D ). NAC treatment reduced lal −/− EC proliferation ( Figure 7E ). Finally, NAC pre-treatment of lal −/− ECs reversed their suppressive activity on T cell proliferation ( Figure 7F ). Taken together, these results support a concept that ROS over-production serves as a mechanism mediating mTOR over-activation in lal −/− EC dysfunctions.
Discussion
LAL is a key enzyme in the metabolic pathway of neutral lipids, and the relationship between LAL and inflammation has been well documented (1, (10) (11) (12) (13) (14) 28) . Genetic ablation of the lal gene in mice has resulted in a systemic increase of MDSCs, causing severe inflammation and pathogenesis in multiple organs (10) . ECs, the major components of blood vessels, are actively involved in inflammation and many other pathogenic conditions. However, the effects of LAL deficiency on EC functions remain to be explored. The major new findings of the present study were that LAL deficiency in ECs 1) enhanced the transendothelial migration of MDSCs, with a concomitant increase of PECAM-1 and ICAM-2 protein levels, 2) impaired in vitro tube-forming capability and in vivo angiogenesis, but increased migration, 3) facilitated cell proliferation, paralleled with reduced apoptosis, and 4) suppressed T cell proliferation and function. The potential mechanisms underlying EC dysfunction were identified, including the interaction with MDSCs, intrinsic over-activation of the mTOR pathway, and cellular overproduction of ROS. lal −/− MDSCs were found to increase transmigration across EC monolayers, promote in vivo angiogenesis, and EC tube formation and proliferation. The mTOR pathway was over-activated in lal −/− ECs, and inhibition of mTOR in lal −/− ECs partially reversed their dysfunctions, including reducing transmigration of MDSCs, EC migration, and suppression of T cell proliferation and function, which was mediated by decreasing ROS production.
Transendothelial migration of leukocytes, or diapedesis, is a critical step in the inflammatory response. The preceding steps of leukocyte rolling, activation, adhesion, and locomotion are all reversible. However, once the leukocytes commit to diapedesis, they do not return to the circulation, at least not as the same cell type (27, 42) . Recent studies have shown that transendothelial migration was promoted by multiple endothelium-derived inflammatory chemokines (43, 44) . Because we previously observed increased MDSC accumulation in the lungs of lal −/− mice (1, 10, 12), we hypothesized that LAL deficiency in ECs would enhance transendothelial migration of MDSCs. In consistence with our hypothesis, MDSCs migrated more efficiently across lal −/− ECs than lal +/+ ECs. In addition, lal −/− MDSCs showed a greater transmigration capability than that of lal +/+ MDSCs ( Figure 1A ). There was a more than 3-fold increase in the transmigration of lal −/− MDSCs across lal −/− ECs than that of lal +/+ MDSCs across lal +/+ ECs, which mimicked the pathological condition of lal −/− mice. Our finding demonstrated that in lal −/− mice, not only myeloid cells but also pulmonary ECs contribute to the increased transendothelial migration, which may explain the increased accumulation of myeloid cells in the bronchoalveolar lavage fluid of lal −/− mice (10).
Several mechanisms are involved in the process of transendothelial migration, among which is the hemophilic interaction of leukocyte PECAM with endothelial PECAM (27) . PECAM-1 is an immunoglobulin superfamily member concentrated at the borders of ECs, as well as diffusely on platelets and leukocytes. Study has shown that when PECAM-PECAM interactions are blocked, leukocytes are arrested tightly adherent to the apical surface of the cell (27, 45) . In the present study, we found that PECAM-1 protein level was increased in lal −/− ECs ( Figure 1C ) and inhibition of PECAM-1 in ECs by siRNA transfection or neutralizing antibodies led to reduced transendothelial migration of lal −/− MDSCs ( Figure 1D-E) , which were consistent with previous findings, suggesting that the elevated expression of PECAM-1 in lal −/− ECs is critical for the enhanced transendothelial migration. We also found that ICAM-2 protein level was increased in lal −/− ECs, whose deletion has been reported to inhibit transmigration of neutrophils (46, 47) . In addition to adhesion molecules in facilitating transendothelial migration of leukocytes, chemokines play an important role in recruiting monocytes, neutrophils, and lymphocytes to the vascular endothelium. MCP-1, acting through its receptor CCR2, has been demonstrated to recruit monocytes into foci of inflammation (48) . The increased level of MCP-1 in lal −/− ECs and CCR2 in lal −/− Ly6G + cells was observed ( Figure 1F-G) . Pre-treatment of ECs with anti-MCP-1 neutralizing antibodies reduced Ly6G + cell transmigration by about 50% ( Figure  1H ). Furthermore, increased production of cytokines IL-6 and TNFα in lal −/− ECs has been observed, and combination of all three neutralizing antibodies further blocked Ly6G + cell transmigration ( Figure 1F and 1H) , demonstrating up-regulated production of chemokines and cytokines in lal −/− ECs is responsible for mediating Ly6G + cell transendothelial migration.
Angiogenesis, the growth of new capillaries from preexisting blood vessels, is a feature of chronic inflammation. ECs are the principle cell population participating in this complex process, which involves EC activation, disruption of vascular basement membranes, migration and proliferation of ECs, and the subsequent formation and maturation of blood vessels (49) . Failure of ECs to adequately perform their angiogenesis-related functions would lead to an imbalance of the angiogenic process, resulting in the pathogenesis of numerous disorders (50) . An important aspect of angiogenesis involves the organization of ECs into three-dimensional tube-like structures. Our results showed that LAL deficiency enhanced EC migration ( Figure 2D ), impaired EC tube formation (Figure 2A) , and decreased in vivo angiogenesis by matrigel plug assay ( Figure 2B-C) .
During the process of angiogenesis, EC proliferation is required to provide the necessary number of cells for new blood vessel formation (51) . However, increased EC proliferation is often related to pathological conditions. In lal −/− mice, it seems that both intrinsic defects and environmental factors contribute to EC proliferation. We observed that there were more pulmonary CD31 + cells, with significantly decreased apoptosis ( Figure 3A and 3D) . After in vitro culture, lal −/− ECs showed enhanced proliferation ( Figure 3B-C) . Furthermore, EC proliferation was greatly increased in the presence of plasma harvested from lal −/− mice. lal −/− ECs co-cultured with plasma from lal −/− mice, a mimic of the in vivo situation of lal −/− mice, showed the greatest proliferation compared with other groups (Figure 3E ), which was in agreement with the in vivo observation that more CD31 + cells existed in the lungs of lal −/− mice ( Figure 3A ). In addition, the up-regulated expression of VEGFR2 in lal −/− ECs was responsible for their higher response to the environmental factors since VEGFR2 knockdown in lal −/− ECs impaired the stimulatory effect of lal −/− plasma on their proliferation (Figure 3 F-G) . Collectively, the above observations suggest that LAL deficiency facilitates EC proliferation and inhibits EC apoptosis, despite the fact that lal −/− ECs had a poor capability of tube formation ( Figure 2A ) and in vivo capillary formation ( Figure 2B ).
ECs, which form the interface between the blood and the underlying tissue, are uniquely positioned for frequent contact with circulating T cells (23) . In lal −/− mice, impairment in T cell proliferation and function has previously been reported (28) . A recent study has found that direct cell-cell contact between ECs and T cells is required for EC-induced T cell proliferation (40) . In our study, lal −/− ECs showed inhibition on T cell proliferation and lymphokine secretion (Figure 4) , which is an additional cellular mechanism of the impaired T cell proliferation in lal −/− mice.
In lal −/− mice, one major manifestation is the massive expansion and infiltration of MDSCs into multiple organs (1, 2, 10, 12, 52 ). Therefore, we speculate that MDSCs from lal −/− mice interact with ECs and influence ECs' functions. Previously, MDSCs isolated from mouse tumors have been reported to induce in vitro angiogenesis by tube formation assay via producing angiogenic factors, including VEGF and bFGF (9) . In the present study, we found that the tube-forming capability of lal −/− ECs was increased after co-culturing with lal −/− MDSCs ( Figure 5A ), and the pro-angiogenic effects of lal −/− MDSCs was mediated by increased production of VEGF ( Figure 5E-F) , suggesting that lal −/− MDSCs had the similar pro-angiogenic effects as tumor-derived MDSCs. The in vivo matrigel plug assay further confirmed the pro-angiogenic activity of lal −/− MDSCs ( Figure 5C-D) . Therefore, in lal −/− mice, compared with ECs' intrinsic angiogenic defect, the pro-angiogenic activity of lal −/− MDSCs contribute to the angiogenesis required for the process of inflammation. lal −/− MDSCs also facilitated EC proliferation ( Figure 5C-D) , which explains why more CD31 + cells existed in the lungs of lal −/− mice ( Figure 3A) . Taken together, MDSC expansion contributes to EC dysfunctions in lal −/− mice.
The mTOR pathway is a key regulator of cell growth and proliferation. Increasing evidence suggests that its dysregulation is associated with human diseases, including metabolic disease, neurodegeneration, aging, cancer, diabetes, and cardiovascular disease (53, 54) . mTOR, defined as a regulatory kinase in ECs, plays an important role in EC survival, migration, and proliferation, and PI3K/AKT/mTOR signaling pathway may regulate PECAM-1 expression in mEC/EB derived ECs (16, 55) . In the present study, we found that the phosphorylation level of mTOR downstream target S6 was significantly increased in lal −/− ECs, which can be reversed after mTOR knocking down by siRNA transfection. Knocking down mTOR in lal −/− ECs partially reversed EC dysfunctions, including decreasing the enhanced transmigration of MDSCs across lal −/− ECs, impairing the increased lal −/− ECs migrating capability and proliferation, and relieving the lal −/− ECs suppression on T cell proliferation and function ( Figure 6C-F) . We have recently reported that over-activation of the mTOR signaling leads to ROS over-production in lal −/− MDSCs (13) . In the present study, ROS over-production was also observed in lal −/− ECs, which was reduced by mTOR inhibitor rapamycin. Neutralization of ROS by antioxidant NAC in lal −/− ECs reversed their dysfunctions (Figure 7 ), similar to those observed in mTOR studies. Therefore, ROS over-production serves as a major mechanism to mediate the mTOR pathway in EC dysfunctions. The above findings provide a mechanistic basis for targeting MDSCs or mTOR or ROS to rejuvenate EC functions in LAL deficiency-related diseases. Clinically, LAL deficiency results in inherited recessive in-born error metabolic diseases: Wolman disease as the infantile on-set and cholesteryl ester storage disease (CESD) as the late on-set. Our lal −/− mice represent Wolman disease biochemically and CESD physiologically. Both enzyme therapy using recombinant human LAL (hLAL) protein and gene therapy using adenovirus-mediated hLAL expression have been successfully tested in lal −/− mouse model (56) (57) (58) . It is conceivable that these strategies can be used to treat EC dysfunctions. In summary, our studies strongly support a concept that neutral lipid metabolism controlled by LAL plays a critical role in maintaining ECs' normal functions by regulation of MDSCs and the mTOR pathway. To block chemokines and cytokines, ECs were pre-treated with 10 μg/mL neutralizing antibody against MCP-1, IL-6, TNF-α individually or in combination, or control IgG for 1 h. Six hours after seeding Ly6G + cells on the EC monolayer, the number of migrating Ly6G + cells was counted. In all above experiments, data were expressed as mean ± SD; n = 4. *P < 0.05, **P < 0.01. 
